Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
bioMerieux (FR:BIM)
PARIS:BIM
Holding FR:BIM?
Track your performance easily
BIM Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€88.25 - €111.50
Previous Close€97.5
Volume34.48K
Average Volume (3M)107.91K
Market Cap
€11.58B
Enterprise Value€11.57B
Total Cash (Recent Filing)€552.60M
Total Debt (Recent Filing)€505.40M
Price to Earnings (P/E)28.1
Beta0.60
Next Earnings
Mar 07, 2025EPS Estimate
€1.91Last Dividend Ex-Date
Jun 07, 2024Dividend Yield0.87%
Share Statistics
EPS (TTM)3.48
Shares OutstandingN/A
10 Day Avg. Volume138,361
30 Day Avg. Volume107,913
Standard Deviation0.08
R-Squared0.00092
Alpha0.00915
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)3.11
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€123.74Price Target Upside28.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
bioMerieux News
PremiumCompany Announcements
bioMérieux’s Strong Growth Continues in 2024
PremiumCompany Announcements
bioMerieux Launches New Vitamin B12 Test
PremiumCompany Announcements
bioMérieux Reports Voting Rights and Shares
PremiumCompany Announcements
bioMerieux Reports Strong H1 2024 Growth
PremiumCompany Announcements
bioMerieux Announces Latest Voting Rights Totals
PremiumCompany Announcements
bioMerieux Advances Rapid Diagnostic Testing
PremiumCompany Announcements
bioMérieux’s VITEK System Wins FDA Clearance
PremiumCompany Announcements
bioMerieux Reports Voting Rights and SharesOptions Prices
Currently, No data available
---
Ownership Overview
―
Insiders
2.58% Mutual Funds
<0.01% Other Institutional Investors
94.52% Public Companies and
Individual Investors
BIM FAQ
What was bioMerieux’s price range in the past 12 months?
bioMerieux lowest stock price was €88.25 and its highest was €111.50 in the past 12 months.
What is bioMerieux’s market cap?
Currently, no data Available
When is bioMerieux’s upcoming earnings report date?
bioMerieux’s upcoming earnings report date is Mar 07, 2025 which is in 105 days.
How were bioMerieux’s earnings last quarter?
bioMerieux released its earnings results on Sep 05, 2024. The company reported €1.82 earnings per share for the quarter, beating the consensus estimate of N/A by €1.82.
Is bioMerieux overvalued?
According to Wall Street analysts bioMerieux’s price is currently Undervalued.
Does bioMerieux pay dividends?
bioMerieux pays a Annually dividend of €0.85 which represents an annual dividend yield of 0.87%. See more information on bioMerieux dividends here
What is bioMerieux’s EPS estimate?
bioMerieux’s EPS estimate is €1.91.
How many shares outstanding does bioMerieux have?
bioMerieux has 118,361,220 shares outstanding.
What happened to bioMerieux’s price movement after its last earnings report?
bioMerieux reported an EPS of €1.82 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 4.175%.
Which hedge fund is a major shareholder of bioMerieux?
Currently, no hedge funds are holding shares in FR:BIM
---
bioMerieux Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€123.74 (28.63% Upside)
€123.74 (28.63% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
2.54%
12-Months-Change
Fundamentals
Return on Equity
10.98%
Trailing 12-Months
Asset Growth
5.73%
Trailing 12-Months
Company Description
bioMerieux
BioMerieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (about 38% of sales), microbiology (about 32%), immunoassays (about 15%), and industrial applications (about 15%). Europe, the Middle East, and Africa accounts for the largest portion of the firm's revenue (38%), followed by North America (38%), Asia-Pacific (17%), and Latin America (7%). BioMerieux is headquartered in Marcy-l'Etoile, France.
---
BIM Stock 12 Month Forecast
Average Price Target
€123.74
▲(28.63% Upside)
Technical Analysis
bioMerieux
―
EKF Diagnostics Holdings
―
Tristel
―
Abingdon Health PLC
―
Cambridge Cognition Holdings
―
Best Analysts Covering BIM
1 Year
1 Year Success Rate
6/9 ratings generated profit
1 Year Average Return
+2.29%
reiterated a buy rating 2 months ago
Copying Robert Davies's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +2.29% per trade.
---